Published in Medicine and Law Weekly, June 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Optimer Pharmaceuticals.
Report 1: Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported that the U.S. Food and Drug Administration has agreed with the recommendation of the independent Data Safety Monitoring Board (DSMB) to advance Difimicin (OPT-80/PAR101) into Phase 3 clinical studies.
The DSMB reviewed the Phase 2b data and stated in their written report, "No safety issues were identified precluding continuation of the study into the phase 3 portion as written in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly